ArticleESMO gastrointestinal oncology2025

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

K Nakanishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.